Lupus Trial, Recruiting NCT07352332 Sponsor: The Children's Hospital of Zhejiang University School of Medicine Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT07352332
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 5 years old or older
  • You have been diagnosed with systemic lupus erythematosus (SLE, a type of autoimmune disease) confirmed using recognised 2019 medical guidelines
  • Your SLE has not responded well to previous treatments, or remains moderately to highly active (this may be measured using a disease activity score — confirm with trial site)
  • Previous treatments tried without enough success may have included steroids, antimalarial drugs, or other medicines that suppress the immune system (confirm with trial site for full list)
  • You are currently receiving a specific type of treatment called a CD3×CD19 BiTE therapy as part of your normal medical care, and records of your dosing and treatment dates are available (confirm with trial site)
  • Blood samples taken before and/or after your BiTE treatment are available, or can be collected during your routine care or follow-up visits
  • You (or your guardian) previously gave permission in a related study or care setting for your biological samples and health information to be stored and used for research, and you are willing to attend follow-up visits

Who may not be able to join:

  • Blood samples cannot be collected in good enough quality — for example, due to too little blood, damaged samples, or poor cell quality
  • You currently have a serious active infection, a sudden worsening of organ function, or another acute medical condition that could affect the blood analysis results
  • Having blood drawn would pose a significant health risk to you — for example, due to severe anaemia, serious blood clotting problems, or another condition the doctor considers too risky
  • Enough health records about your condition (such as disease activity scores, kidney results, or relevant blood test results) are not available
  • Your parent or legal guardian does not agree to your participation, withdraws permission for use of your samples, or — where relevant — you as a child do not agree to take part
  • Any other reason the trial doctor believes could affect your safety, the quality of the data, or your ability to complete the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 81732489

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in proportions and phenotypic characteristics of peripheral blood immune cell subsets

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov